QQQ   311.37 (-0.11%)
AAPL   156.95 (+4.06%)
MSFT   263.18 (-0.54%)
META   193.83 (+2.68%)
GOOGL   107.34 (-0.37%)
AMZN   108.10 (-4.26%)
TSLA   197.74 (+5.03%)
NVDA   216.18 (-0.42%)
NIO   11.74 (-1.84%)
BABA   107.08 (-2.42%)
AMD   87.86 (-0.51%)
T   19.88 (-1.97%)
F   13.49 (-5.80%)
MU   63.56 (+0.62%)
CGC   3.06 (-2.55%)
GE   82.94 (-1.19%)
DIS   112.50 (-0.63%)
AMC   6.68 (+9.87%)
PFE   44.19 (-0.34%)
PYPL   87.71 (+0.86%)
NFLX   377.39 (+2.86%)
QQQ   311.37 (-0.11%)
AAPL   156.95 (+4.06%)
MSFT   263.18 (-0.54%)
META   193.83 (+2.68%)
GOOGL   107.34 (-0.37%)
AMZN   108.10 (-4.26%)
TSLA   197.74 (+5.03%)
NVDA   216.18 (-0.42%)
NIO   11.74 (-1.84%)
BABA   107.08 (-2.42%)
AMD   87.86 (-0.51%)
T   19.88 (-1.97%)
F   13.49 (-5.80%)
MU   63.56 (+0.62%)
CGC   3.06 (-2.55%)
GE   82.94 (-1.19%)
DIS   112.50 (-0.63%)
AMC   6.68 (+9.87%)
PFE   44.19 (-0.34%)
PYPL   87.71 (+0.86%)
NFLX   377.39 (+2.86%)
QQQ   311.37 (-0.11%)
AAPL   156.95 (+4.06%)
MSFT   263.18 (-0.54%)
META   193.83 (+2.68%)
GOOGL   107.34 (-0.37%)
AMZN   108.10 (-4.26%)
TSLA   197.74 (+5.03%)
NVDA   216.18 (-0.42%)
NIO   11.74 (-1.84%)
BABA   107.08 (-2.42%)
AMD   87.86 (-0.51%)
T   19.88 (-1.97%)
F   13.49 (-5.80%)
MU   63.56 (+0.62%)
CGC   3.06 (-2.55%)
GE   82.94 (-1.19%)
DIS   112.50 (-0.63%)
AMC   6.68 (+9.87%)
PFE   44.19 (-0.34%)
PYPL   87.71 (+0.86%)
NFLX   377.39 (+2.86%)
QQQ   311.37 (-0.11%)
AAPL   156.95 (+4.06%)
MSFT   263.18 (-0.54%)
META   193.83 (+2.68%)
GOOGL   107.34 (-0.37%)
AMZN   108.10 (-4.26%)
TSLA   197.74 (+5.03%)
NVDA   216.18 (-0.42%)
NIO   11.74 (-1.84%)
BABA   107.08 (-2.42%)
AMD   87.86 (-0.51%)
T   19.88 (-1.97%)
F   13.49 (-5.80%)
MU   63.56 (+0.62%)
CGC   3.06 (-2.55%)
GE   82.94 (-1.19%)
DIS   112.50 (-0.63%)
AMC   6.68 (+9.87%)
PFE   44.19 (-0.34%)
PYPL   87.71 (+0.86%)
NFLX   377.39 (+2.86%)
NASDAQ:CRSP

CRISPR Therapeutics - CRSP Stock Forecast, Price & News

$56.01
-0.11 (-0.20%)
(As of 02/3/2023 11:47 AM ET)
Add
Compare
Today's Range
$53.38
$56.11
50-Day Range
$39.19
$56.12
52-Week Range
$38.94
$86.95
Volume
488,796 shs
Average Volume
1.07 million shs
Market Capitalization
$4.39 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$98.22

CRISPR Therapeutics MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.53 Rating Score
Upside/​Downside
80.7% Upside
$98.22 Price Target
Short Interest
Healthy
13.16% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.23mentions of CRISPR Therapeutics in the last 14 days
Based on 9 Articles This Week
Insider Trading
Selling Shares
$3.66 M Sold Last Quarter
Proj. Earnings Growth
Growing
From ($9.25) to ($8.21) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.04 out of 5 stars

Medical Sector

515th out of 1,029 stocks

Biological Products, Except Diagnostic Industry

82nd out of 169 stocks

CRSP stock logo

About CRISPR Therapeutics (NASDAQ:CRSP) Stock

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Receive CRSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRSP Stock News Headlines

Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
CRISPR Therapeutics AG (NASDAQ:CRSP) Short Interest Update
Know Your Profit Potential BEFORE You Trade!
I’m Chuck Hughes, ten-time trading champion and author of the coveted e-book, “Options Trading Made Easy”, the strategy guide that will teach you to calculate your trade’s profit potential before you risk any capital. Click here for a free copy now! pixel
3 CRISPR Stocks That Will Make You Filthy Rich in 10 Years
Prime Medicine 'Crispr 3.0' Vs. Crispr Therapeutics
3 Beaten-Down Stocks That Could Explode Higher in 2023
Needham Reaffirms Their Buy Rating on Crispr Therapeutics AG (CRSP)
3 Healthcare Stocks That Could Go Parabolic
Expert Ratings for CRISPR Therapeutics
What 8 Analyst Ratings Have To Say About CRISPR Therapeutics
See More Headlines
Receive CRSP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CRISPR Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CRSP Company Calendar

Last Earnings
11/03/2021
Today
2/03/2023
Next Earnings (Estimated)
2/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CRSP
Fax
N/A
Employees
473
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$98.22
High Stock Price Forecast
$220.00
Low Stock Price Forecast
$37.00
Forecasted Upside/Downside
+75.4%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.53
Research Coverage
17 Analysts

Profitability

Net Income
$377.66 million
Net Margins
-4,831.79%
Pretax Margin
-4,782.84%

Debt

Sales & Book Value

Annual Sales
$914.96 million
Cash Flow
$5.73 per share
Book Value
$31.35 per share

Miscellaneous

Free Float
74,144,000
Market Cap
$4.39 billion
Optionable
Optionable
Beta
1.66

Key Executives

  • Dr. Rodger Novak M.D. (Age 55)
    Founder, Chairman & Pres
  • Dr. Samarth  KulkarniDr. Samarth Kulkarni (Age 43)
    CEO & Director
    Comp: $1.18M
  • Dr. Lawrence Otto Klein Ph.D.Dr. Lawrence Otto Klein Ph.D. (Age 40)
    Chief Operating Officer
    Comp: $675k
  • Mr. James R. KasingerMr. James R. Kasinger (Age 50)
    Gen. Counsel & Sec.
    Comp: $648.93k
  • Mr. Shaun Foy
    Founder
  • Dr. Emmanuelle Marie Charpentier
    Co-Founder & Scientific Advisory Board Member
  • Dr. Craig C. Mello Ph.D.
    Scientific Founder & Advisory Board Member
  • Dr. Chad Cowan Ph.D.
    Scientific Founder
  • Dr. Matthew Porteus M.D. (Age 56)
    Ph.D., Scientific Founder & Advisory Board Member
  • Dr. Daniel G. Anderson Ph.D.
    Scientific Founder & Advisory Board Member













CRSP Stock - Frequently Asked Questions

Should I buy or sell CRISPR Therapeutics stock right now?

17 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for CRISPR Therapeutics in the last year. There are currently 1 sell rating, 6 hold ratings and 10 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRSP shares.
View CRSP analyst ratings
or view top-rated stocks.

What is CRISPR Therapeutics' stock price forecast for 2023?

17 Wall Street analysts have issued 12-month target prices for CRISPR Therapeutics' shares. Their CRSP share price forecasts range from $37.00 to $220.00. On average, they anticipate the company's stock price to reach $98.22 in the next year. This suggests a possible upside of 75.0% from the stock's current price.
View analysts price targets for CRSP
or view top-rated stocks among Wall Street analysts.

How have CRSP shares performed in 2023?

CRISPR Therapeutics' stock was trading at $40.65 on January 1st, 2023. Since then, CRSP shares have increased by 38.1% and is now trading at $56.12.
View the best growth stocks for 2023 here
.

Are investors shorting CRISPR Therapeutics?

CRISPR Therapeutics saw a decline in short interest during the month of January. As of January 15th, there was short interest totaling 9,880,000 shares, a decline of 5.7% from the December 31st total of 10,480,000 shares. Based on an average daily trading volume, of 1,080,000 shares, the short-interest ratio is presently 9.1 days. Approximately 13.2% of the company's shares are short sold.
View CRISPR Therapeutics' Short Interest
.

When is CRISPR Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 21st 2023.
View our CRSP earnings forecast
.

How were CRISPR Therapeutics' earnings last quarter?

CRISPR Therapeutics AG (NASDAQ:CRSP) released its earnings results on Wednesday, November, 3rd. The company reported ($1.67) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.75) by $0.08. The company earned $0.82 million during the quarter, compared to analyst estimates of $3.85 million. CRISPR Therapeutics had a negative trailing twelve-month return on equity of 31.34% and a negative net margin of 4,831.79%.

What other stocks do shareholders of CRISPR Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CRISPR Therapeutics investors own include NVIDIA (NVDA), Editas Medicine (EDIT), Alibaba Group (BABA), Micron Technology (MU), Advanced Micro Devices (AMD), Block (SQ), Tesla (TSLA), Intellia Therapeutics (NTLA), QUALCOMM (QCOM) and Shopify (SHOP).

When did CRISPR Therapeutics IPO?

(CRSP) raised $75 million in an initial public offering on Wednesday, October 19th 2016. The company issued 4,700,000 shares at $15.00-$17.00 per share. Citigroup, Piper Jaffray and Barclays served as the underwriters for the IPO and Guggenheim Securities was co-manager.

What is CRISPR Therapeutics' stock symbol?

CRISPR Therapeutics trades on the NASDAQ under the ticker symbol "CRSP."

Who are CRISPR Therapeutics' major shareholders?

CRISPR Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include ARK Investment Management LLC (10.00%), Sumitomo Mitsui Trust Holdings Inc. (5.12%), Baillie Gifford & Co. (0.34%), Allspring Global Investments Holdings LLC (0.33%), Capital Advisors Inc. OK (0.17%) and Simplex Trading LLC (0.00%). Insiders that own company stock include Bradley J Phd Bolzon, Bradley J Phd Bolzon, James R Kasinger, Lawrence Otto Klein, Michael John Tomsicek, Rodger Novak, Samarth Kulkarni, Tony W Ho and Tony W Ho.
View institutional ownership trends
.

How do I buy shares of CRISPR Therapeutics?

Shares of CRSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CRISPR Therapeutics' stock price today?

One share of CRSP stock can currently be purchased for approximately $56.12.

How much money does CRISPR Therapeutics make?

CRISPR Therapeutics (NASDAQ:CRSP) has a market capitalization of $4.39 billion and generates $914.96 million in revenue each year. The company earns $377.66 million in net income (profit) each year or ($8.80) on an earnings per share basis.

How many employees does CRISPR Therapeutics have?

The company employs 473 workers across the globe.

How can I contact CRISPR Therapeutics?

CRISPR Therapeutics' mailing address is BAARERSTRASSE 14, ZUG V8, CH-6300. The official website for the company is www.crisprtx.com. The company can be reached via phone at (141) 561-3277 or via email at susan.kim@crisprtx.com.

This page (NASDAQ:CRSP) was last updated on 2/3/2023 by MarketBeat.com Staff